Protagonist Therapeutics, Inc — Director's Dealing 2016

Aug 17, 2016

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Protagonist Therapeutics, Inc (PTGX)
CIK: 0001377121
Period of Report: 2016-08-16

Reporting Person: Papanek Julie (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2016-08-16	Common Stock	C	1869922	—	Acquired	1869922	Indirect
2016-08-16	Common Stock	P	583333	$12.00	Acquired	2453255	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2016-08-16	Series C Preferred Stock	$	C	27113877	Disposed		Common Stock (1869922)	Indirect

Footnotes

F1: The number of shares of common stock reflects a 1-for-14.5 reverse stock split, which became effective on August 1, 2016. Pursuant to the reverse stock split, every 14.5 shares of Preferred Stock converted into one share of common stock of the Issuer at the closing of the Issuer's initial public offering.

F2: Each share of the Issuer's Series C Preferred Stock, which had no expiration date, automatically converted into the Issuer's common stock on a 1-for-14.5 basis at the closing of the Issuer's initial public offering, for no additional consideration.

F3: These shares are held directly by Canaan X L.P. (the "Canaan Fund"). The Reporting Person is a non-managing member of Canaan Partners X LLC, the general partner of the Canaan Fund. The Reporting Person does not have voting, investment or dispositive power over any of the shares directly held by the Canaan Fund and disclaims beneficial ownership of the shares except to the extent of her pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.